Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | SRC | P12931 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 7/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9414571 | 0.81 | KDM4E (0.65) | KDM4ESRCMEN1KMT2AHTT | |
| SCHEMBL25348379 | 0.80 | SRC (0.61) | KDM4ESRCMEN1KMT2AHTT | |
| SCHEMBL28670802 | 0.78 | MEN1 (0.60) | KDM4ESRCMEN1KMT2AHTT | |
| SCHEMBL9463348 | 0.78 | KDM4E (0.57) | KDM4ESRCMEN1KMT2AHTT | |
| SCHEMBL17322734 | 0.77 | KDM4E (0.61) | KDM4ESRCMEN1KMT2AHTT | |
| SCHEMBL14577795 | 0.77 | KDM4E (0.61) | KDM4ESRCMEN1KMT2AHTT | |
| SCHEMBL7198391 | 0.76 | SRC (0.70) | KDM4ESRCL3MBTL1TDP1ALDH1A1 | |
| Phenyl Dihydrogen Phosphate SCHEMBL2462548 | 0.76 | SRC (0.95) | KDM4ESRCL3MBTL1TDP1ALDH1A1 | |
| Phenyl Dihydrogen Phosphate SCHEMBL28079517 | 0.76 | SRC (0.95) | KDM4ESRCL3MBTL1TDP1ALDH1A1 | |
| SCHEMBL132235 | 0.76 | KDM4E (0.92) | KDM4ESRCMEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119241622-B | 3′-ONH2Synthesis method of ribonucleotide | 凯莱英生命科学技术(天津)有限公司 | 2025-04-18 | — | — | CN | claimed |
| CN-119751445-A | Preparation method of 6-ethynyl pyrazolo [1,5-a ] pyridine | 江南大学 | 2025-04-04 | — | — | CN | claimed |
| CN-119241622-A | 3′-ONH2Synthesis method of ribonucleotide | 凯莱英生命科学技术(天津)有限公司 | 2025-01-03 | — | — | CN | claimed |
| CN-118164864-A | Luo Shasi and process for the preparation of intermediates therefor | 北京海美源医药科技有限公司 | 2024-06-11 | — | — | CN | claimed |
| CN-115353184-B | Surface modified chitosan-agar flocculant and preparation method and application thereof | 湖南仁和环境股份有限公司 | 2024-01-26 | — | — | CN | claimed |
| CN-117285542-A | Preparation method of balo Sha Weizhi and key intermediate thereof | 广西天铭药业有限公司 | 2023-12-26 | — | — | CN | claimed |
| CN-113620274-A | Method for preparing lignin-based carbon quantum dots with high quantum yield quickly, simply and conveniently | 广东工业大学 | 2021-11-09 | — | — | CN | claimed |
| CN-121779214-A | Deamination synthesis method of difluoromethyl ketone compound | 河南医药大学 | 2026-04-03 | — | — | CN | disclosed |
| CN-119241622-B | 3′-ONH2Synthesis method of ribonucleotide | 凯莱英生命科学技术(天津)有限公司 | 2025-04-18 | — | — | CN | disclosed |
| CN-119751445-A | Preparation method of 6-ethynyl pyrazolo [1,5-a ] pyridine | 江南大学 | 2025-04-04 | — | — | CN | disclosed |
| CN-119241622-A | 3′-ONH2Synthesis method of ribonucleotide | 凯莱英生命科学技术(天津)有限公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-118373784-B | One-pot preparation method of 2-aryl benzoxazole and asymmetric sulfoxide | 江苏师范大学 | 2024-09-03 | — | — | CN | disclosed |
| CN-118373784-A | One-pot preparation method of 2-aryl benzoxazole and asymmetric sulfoxide | 江苏师范大学 | 2024-07-23 | — | — | CN | disclosed |
| US-6670357-B2 | Antiinflammatory agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-30 | — | — | US | disclosed |
| EP-1363910-A2 | METHODS OF TREATING P38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20030069244-A1 | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-10 | — | — | US | disclosed |
| EP-1183033-A4 | PYRROLOTRIAZINE INHIBITORS OF KINASES | BRISTOL MYERS SQUIBB CO (US) | 2002-07-17 | — | — | EP | disclosed |
| WO-2002040486-A2 | METHODS OF TREATING p38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-05-23 | — | — | WO | disclosed |
| EP-1183033-A1 | PYRROLOTRIAZINE INHIBITORS OF KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000071129-A1 | PYRROLOTRIAZINE INHIBITORS OF KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069244-A1 | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors | MAPK1, MAPK3, MAPK6 | KDM4E 2869/4885SRC 232/4885MEN1 2998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.